Table 1

Treatment arms of terbinafine included in pooled estimates
Treatment
Arm*

 Sample Size
(No. of Patients – ni)

 No. of Treatment
Termination Due to
Adverse Effect (xi)
 Proportion of Treatment
Termination (pi = xi/ni)
1
 184
 7
 3.80%
2
 65
 1
 1.54%
3
 33
 1
 3.03%
4
 151
 4
 2.65%
5
 24
 0
 0.00%
6
 30
 0
 0.00%
7
 20
 0
 0.00%
8
 22
 0
 0.00%
9
 50
 4
 8.00%
10
 50
 5
 10.00%
11
 18
 0
 0.00%
12
 26
 0
 0.00%
13
 72
 0
 0.00%
14
 30
 1
 3.33%
15
 16
 0
 0.00%
16
 26
 2
 7.69%
17
 95
 8
 8.42%
18
 95
 3
 3.16%
19
 186
 0
 0.00%
20
 146
 11
 7.53%
21
 142
 2
 1.41%
22
 124
 8
 6.45%
23
 56
 1
 1.79%
24
 12
 0
 0.00%
25
 50
 0
 0.00%
26
 88
 3
 3.41%
27
 48
 0
 0.00%
28
 75
 4
 5.33%
29
 76
 0
 0.00%
30
 56
 1
 1.79%
31
 153
 9
 5.88%
32
 68
 1
 1.47%
33
 120
 13
 10.83%
34
 44
 0
 0.00%
35
 84
 0
 0.00%
36
 21
 0
 0.00%
37
 145
 3
 2.07%
38
 83
 10
 12.05%
39
 68
 3
 4.41%
40
 30
 3
 10.00%
41
 120
 3
 2.50%

*Referenced separately in appendix

Young-Xu and Chan BMC Medical Research Methodology 2008 8:58   doi:10.1186/1471-2288-8-58